Christian M Jespersen

Summary

Country: Denmark

Publications

  1. ncbi Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial
    Christian M Jespersen
    Bispebjerg Hospital, Copenhagen University Hospital, Department of Cardiology Y, Bispebjerg Bakke 23, DK 2400 Copenhagen, Denmark
    BMJ 332:22-7. 2006
  2. ncbi Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial
    Jørgen Hilden
    The Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, DK 2100 Copenhagen, Denmark
    Diagn Microbiol Infect Dis 66:385-92. 2010
  3. ncbi Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease
    Gorm B Jensen
    Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Denmark
    J Cardiovasc Pharmacol 55:123-8. 2010
  4. ncbi Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease
    Christian Gluud
    The Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Cardiology 111:280-7. 2008
  5. ncbi The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease
    Naja Dam Mygind
    Cardiac Catheterization Laboratory 2014, Department of Medicine B, Faculty of Health Sciences, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark
    Inflamm Res 60:281-7. 2011
  6. ncbi Myocardial stress in patients with acute cerebrovascular events
    Christian M Jespersen
    Global Development, Novo Nordisk, Bagsvaerd, Denmark
    Cardiology 110:123-8. 2008

Collaborators

Detail Information

Publications6

  1. ncbi Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial
    Christian M Jespersen
    Bispebjerg Hospital, Copenhagen University Hospital, Department of Cardiology Y, Bispebjerg Bakke 23, DK 2400 Copenhagen, Denmark
    BMJ 332:22-7. 2006
    ..To determine if the macrolide clarithromycin affects mortality and cardiovascular morbidity in patients with stable coronary heart disease...
  2. ncbi Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial
    Jørgen Hilden
    The Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, DK 2100 Copenhagen, Denmark
    Diagn Microbiol Infect Dis 66:385-92. 2010
    ..Smoking-related lung disease probably underlies the link between heart disease and increased IgG titers...
  3. ncbi Statin treatment prevents increased cardiovascular and all-cause mortality associated with clarithromycin in patients with stable coronary heart disease
    Gorm B Jensen
    Department of Cardiology, Hvidovre Hospital, Copenhagen University Hospital, Denmark
    J Cardiovasc Pharmacol 55:123-8. 2010
    ..41). Multivariate analysis and 6-year follow up confirmed these results. Concomitant statin treatment in stable patients with coronary heart disease abrogated the observed increased CV mortality associated with 2 weeks of clarithromycin...
  4. ncbi Clarithromycin for 2 weeks for stable coronary heart disease: 6-year follow-up of the CLARICOR randomized trial and updated meta-analysis of antibiotics for coronary heart disease
    Christian Gluud
    The Copenhagen Trial Unit, Center for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
    Cardiology 111:280-7. 2008
    ..Here we report the 6-year mortality of clarithromycin- versus placebo-exposed patients and updated meta-analyses...
  5. ncbi The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease
    Naja Dam Mygind
    Cardiac Catheterization Laboratory 2014, Department of Medicine B, Faculty of Health Sciences, The Heart Centre, Rigshospitalet, Copenhagen University Hospital, Blegdamsvej 9, 2100 Copenhagen Ø, Denmark
    Inflamm Res 60:281-7. 2011
    ..The aim was to investigate the influence of statin treatment and lipid status on serum YKL-40 and Hs-CRP in patients with stable CAD...
  6. ncbi Myocardial stress in patients with acute cerebrovascular events
    Christian M Jespersen
    Global Development, Novo Nordisk, Bagsvaerd, Denmark
    Cardiology 110:123-8. 2008
    ..However, all patients with signs of cardiac involvement during acute cerebrovascular events should receive a cardiological follow-up in order to exclude concomitant ischemic heart disease...